Dr Reddy’s Laboratories Ltd announced the launch of authorized generic version of NitroDur (nitroglycerin) transdermal infusion system.



Dr Reddy’s nitroglycerin transdermal infusion system is available in four dosage strengths: 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, and 0.6 mg/hr, each in a box of 30 count.



NitroDur is a trademark of US Pharma Ltd.



The combined market for all nitrogylcerin transdermal patch products had US sales of approximately $14.7 million MAT for the most recent twelve months ending in January 2020, according to IQVIA Health.



Dr. Reddy’s Laboratories is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - pharmaceutical services and active ingredients, global generics and proprietary products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.